A research team headed by the University of Zurich has developed a powerful new method to precisely edit DNA by combining ...

CRISPR Therapeutics’ CRSP Casgevy, a one-shot gene therapy, was approved in late 2023 and early 2024 across the United States and Europe for two blood disorder indications — sickle cell disease (SCD) ...

A Chinese scientist, He Jiankui, made a shocking announcement to the world in 2018: He had secretly engineered the birth of the first gene-edited babies. The birth of the twins was seen as reckless ...

CRISPR offers the power to rewrite life’s code, promising cures for deadly diseases—but also the potential for devastating misuse when combined with AI.

A large language model can design and troubleshoot CRISPR protocols from scratch, allowing first-time researchers to achieve ...

CRISPR, researchers identified Laccase2 as essential for hardening and darkening overwintering eggs in pea aphids. Knockout ...

Surviving the harsh winter months is a major challenge for many insects. One widely adopted survival strategy, especially in ...

Mars partners with Pairwise to use CRISPR tech for developing disease- and climate-resilient cacao, aiming to secure future ...

Researchers at the Salk Institute have used CRISPR to uncover hidden microproteins that control fat cell growth and lipid storage, identifying one confirmed target, Adipocyte-smORF-1183. This ...

The multiagent AI system, dubbed “CRISPR-GPT,” is designed to interact and reason with human users as they execute ...

Biotechnology outfit CRISPR Therapeutics (NASDAQ: CRSP) isn't a name on many investors' radar -- and understandably so. Its market capitalization is a mere $6 billion. The company ...